Determinants of BH3 binding specificity for Mcl-1 versus Bcl-xL
- PMID: 20363230
- PMCID: PMC2896288
- DOI: 10.1016/j.jmb.2010.03.058
Determinants of BH3 binding specificity for Mcl-1 versus Bcl-xL
Abstract
Interactions among Bcl-2 family proteins are important for regulating apoptosis. Prosurvival members of the family interact with proapoptotic BH3 (Bcl-2-homology-3)-only members, inhibiting execution of cell death through the mitochondrial pathway. Structurally, this interaction is mediated by binding of the alpha-helical BH3 region of the proapoptotic proteins to a conserved hydrophobic groove on the prosurvival proteins. Native BH3-only proteins exhibit selectivity in binding prosurvival members, as do small molecules that block these interactions. Understanding the sequence and structural basis of interaction specificity in this family is important, as it may allow the prediction of new Bcl-2 family associations and/or the design of new classes of selective inhibitors to serve as reagents or therapeutics. In this work, we used two complementary techniques--yeast surface display screening from combinatorial peptide libraries and SPOT peptide array analysis--to elucidate specificity determinants for binding to Bcl-x(L)versus Mcl-1, two prominent prosurvival proteins. We screened a randomized library and identified BH3 peptides that bound to either Mcl-1 or Bcl-x(L) selectively or to both with high affinity. The peptides competed with native ligands for binding into the conserved hydrophobic groove, as illustrated in detail by a crystal structure of a specific peptide bound to Mcl-1. Mcl-1-selective peptides from the screen were highly specific for binding Mcl-1 in preference to Bcl-x(L), Bcl-2, Bcl-w, and Bfl-1, whereas Bcl-x(L)-selective peptides showed some cross-interaction with related proteins Bcl-2 and Bcl-w. Mutational analyses using SPOT arrays revealed the effects of 170 point mutations made in the background of a peptide derived from the BH3 region of Bim, and a simple predictive model constructed using these data explained much of the specificity observed in our Mcl-1 versus Bcl-x(L) binders.
(c) 2010 Elsevier Ltd. All rights reserved.
Figures
Similar articles
-
Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands.J Biol Chem. 2005 Feb 11;280(6):4738-44. doi: 10.1074/jbc.M411434200. Epub 2004 Nov 18. J Biol Chem. 2005. PMID: 15550399
-
In silico and in vitro elucidation of BH3 binding specificity toward Bcl-2.Biochemistry. 2012 Jul 24;51(29):5841-50. doi: 10.1021/bi3003567. Epub 2012 Jul 12. Biochemistry. 2012. PMID: 22702834 Free PMC article.
-
Genome-wide prediction and validation of peptides that bind human prosurvival Bcl-2 proteins.PLoS Comput Biol. 2014 Jun 26;10(6):e1003693. doi: 10.1371/journal.pcbi.1003693. eCollection 2014 Jun. PLoS Comput Biol. 2014. PMID: 24967846 Free PMC article.
-
Structural biology of the Bcl-2 family of proteins.Biochim Biophys Acta. 2004 Mar 1;1644(2-3):83-94. doi: 10.1016/j.bbamcr.2003.08.012. Biochim Biophys Acta. 2004. PMID: 14996493 Review.
-
What can we learn from mice lacking pro-survival BCL-2 proteins to advance BH3 mimetic drugs for cancer therapy?Cell Death Differ. 2022 Jun;29(6):1079-1093. doi: 10.1038/s41418-022-00987-0. Epub 2022 Apr 6. Cell Death Differ. 2022. PMID: 35388168 Free PMC article. Review.
Cited by
-
Stapled BH3 peptides against MCL-1: mechanism and design using atomistic simulations.PLoS One. 2012;7(8):e43985. doi: 10.1371/journal.pone.0043985. Epub 2012 Aug 31. PLoS One. 2012. PMID: 22952838 Free PMC article.
-
Conversion of cell-survival activity of Akt into apoptotic death of cancer cells by two mutations on the BIM BH3 domain.Cell Death Dis. 2015 Jul 2;6(7):e1804. doi: 10.1038/cddis.2015.118. Cell Death Dis. 2015. PMID: 26136077 Free PMC article.
-
Molecular evolution of peptides by yeast surface display technology.Medchemcomm. 2019 Jul 10;10(9):1569-1580. doi: 10.1039/c9md00252a. eCollection 2019 Sep 1. Medchemcomm. 2019. PMID: 31803399 Free PMC article. Review.
-
Peptide design by optimization on a data-parameterized protein interaction landscape.Proc Natl Acad Sci U S A. 2018 Oct 30;115(44):E10342-E10351. doi: 10.1073/pnas.1812939115. Epub 2018 Oct 15. Proc Natl Acad Sci U S A. 2018. PMID: 30322927 Free PMC article.
-
ADRB2-Targeting Therapies for Prostate Cancer.Cancers (Basel). 2019 Mar 13;11(3):358. doi: 10.3390/cancers11030358. Cancers (Basel). 2019. PMID: 30871232 Free PMC article. Review.
References
-
- Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322–6. - PubMed
-
- Huang DC, Strasser A. BH3-Only proteins-essential initiators of apoptotic cell death. Cell. 2000;103:839–42. - PubMed
-
- Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002;2:183–92. - PubMed
-
- Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677–81. - PubMed
-
- Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, Elmore SW. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421–8. - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
